If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Eli Lilly and Company does not control, influence, or endorse this site, and the opinions, claims or comments expressed on this site should not be attributed to Eli Lilly and Company. Eli Lilly and Company is not responsible for the privacy policy of any third party web sites. We encourage you to read the privacy policy of every web site you visit.
Menu closed
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
ZypAdhera ® (olanzapine pamoate monohydrate)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
ZypAdhera Summary of Product Characteristics (SmPC)
ZypAdhera® (olanzapine pamoate): More or all solvent used
There is more diluent in the diluent vial than is needed to complete the reconstitution. If more diluent is added than directed in the instructions for use, the final dose will be less than 150 mg/ml. This can lead to an incorrect dose being administered.
Further
Information
Lilly
cannot provide guidance to use the product in a way that is not
specified in the label.1
Solvent
Volume for Reconstitution
Table
1 provides the amount of solvent required to reconstitute
olanzapine pamoate powder for prolonged release suspension for
injection.2
Table
1. Determine the amount of solvent required to reconstitute
olanzapine pamoate powder for prolonged release suspension for
injection.2
ZypAdhera
vial strength (mg)
Volume
of solvent to add (ml)
210
1.3
300
1.8
405
2.3
It is
important to note that there is more solvent in the vial than is
needed to reconstitute.
Each
vial of solvent across all strengths contains 3 ml of solvent.2
After
reconstitution as directed in the label, each ml of suspension
contains 150 mg olanzapine.2
References
1.
Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2.
ZypAdhera [summary of product characteristics] Eli Lilly Netherland
B.V., The Netherlands.
Date of Last Review:February 13, 2020
Are you satisfied with this content?
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com